Supplementary Results from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer

Michelle Melino; Wen Juan Tu; Helle Bielefeldt‐Ohmann; Martina Proctor; Taniya Ahuja; John Vandermeide; Amanda L. Bain; Gahyathiri Nallan; Sal Lee Goh; Thiru Prasanna; Jane E. Dahlstrom; Mariska Miranda; Ramesh Kumar Chaudhary; Aravind Anandam; Sumit Chaudhary; Jonathan T. Seal; Debottam Sinha; Shaoqian Zhang; Tam Hong Nguyen; Sriganesh Srihari; Günter Härtel; Amy Ives; Laeeq Malik; Desmond Yip; Michelle Nottage; Melissa Eastgate; Sudha Rao

doi:10.1158/1535-7163.30255310

Key Points

Targeting EZH2 through PI3K–mTOR inhibition may help reduce metastasis in triple-negative breast cancer.
Supplementary results support the role of EZH2 in mediating immunotherapy resistance, suggesting therapeutic intervention.
The findings indicate a potential strategy for enhancing treatment response in aggressive breast cancer by addressing multiple resistance mechanisms.
Emerging insights from the supplementary data emphasize the need for focused research on combined treatment approaches.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Supplementary results reveal that targeting EZH2 and PI3K–mTOR may improve outcomes in triple-negative breast cancer, highlighting strategy against metastasis and immunotherapy resistance.

Abstract

Supplementary Results to accompany manuscript

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Melino et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21a0c https://doi.org/10.1158/1535-7163.30255310

View Full Paper

Ask AI

Bookmark

Share

Supplementary Results from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Results from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers